The potential for experimental research to identify new safety biomarkers or dosing strategies for minimizing toxicities of oncology therapies as an essential expanded focus for qualityof-life research remains largely unrealized. We believe that, with resources and prioritization, researchers can make real progress in this space. The impact of mechanistic and translational studies on anthracyclines is a case in point. When use of the anthracycline doxorubicin as an antineoplastic agent was launched more than 40 years ago, it quickly became evident that cardiotoxicity would be dose limiting. Studies in Syrian golden hamsters and rhesus monkeys soon replicated the drug's acute arrhythmogenic effects and became the launching point for exploration of dexrazoxane as a potential protective inhibitor of these cardiotoxicities. Further work in a range of preclinical animal models and in vitro assays has identified monitorable serum biomarkers of doxorubicin-induced toxicities, elucidated the protective pharmacology of dexrazoxane (iron chelation and topoisomerase II inhibition), provided proof of concept for different dose-optimization strategies, and characterized the mechanism of latent doxorubicininduced cardiotoxicity (accumulated mitochondrial damage). Cumulatively, these findings have yielded dramatic changes in clinical dosing practices for doxorubicin and spurred the use of protective therapies such as dexrazoxane to enhance antineoplastic efficacy while reducing both acute and delayed adverse effects (7) .
Currently, the U.S. National Cancer Institute's Provocative Questions initiative (PQ 9 specifically) and innovative seed-funding programs such as the HESI-Pardee THRIVE Initiative are among a very few that provide much needed, albeit modest, research funding in this space. Efforts led by the International CardiOncology Society, THRIVE, Friends of Cancer Research, and others add further depth of field by creating new, multidisciplinary communities of practice to synergize expertise and applications. There is a growing network of expertise behind the prevention, prediction, and management of treatment-related toxicities that can limit patient adherence to treatment or a survivor's ability to thrive after treatment.
The need for, and the achievability of, a quality-of-life-driven research agenda has never been stronger. By increasing the rigor, visibility, and frequency of this research, we also increase the potential to both broaden the lifetime benefit of existing cancer treatments and enhance the reach of future therapies.
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